News & Articles

Two different dosing regimens demonstrated efficacy with one showing a better profile

The collaboration aims to secure manufacturing and testing capacity in the next phase of the pandemic

Observations of rapid recovery on chest x-rays noted and no drug-related Serious Adverse Events reported

Test adds to QIAGEN’s growing portfolio of PCR testing solutions for COVID-19 testing

QIAreach SARS-CoV-2 Antigen Test is an important step towards decentralized mass screening by processing samples in 2–15 minutes

Phase 3 part of clinical trial to enrol over 30,000 volunteers worldwide

Collaboration to develop next-generation CAR-T cell therapies with improved efficacy and durability

The new IgM antibody test demonstrated 99.9% specificity with 1,400 negative samples and 100% sensitivity at >18 days post symptom onset and post positive PCR

To expand Minimally Invasive Surgery field by reinforcing its orthopedics business

Study by University of Manchester reassures patients that it is safe to take blood pressure medication during the pandemic

New kit aims to provide highly sensitive and efficient approach for studying mitophagy impairment in conditions such as Parkinson’s and Alzheimer’s

The collaboration will focus on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy

Veklury is first FDA-approved treatment for COVID-19 in the US, and aims to shorten time to recovery by five days

The hypercube algorithm aims to enable regular, cost-effective screening in multiple contexts

The test uses a convolutional neural network to classify microscopy images of single intact particles of different viruses

Easy-to-use test, which doesn't require specialized laboratory personnel or instruments, promises flexibility to test in locations that benefit from immediate results

The CTS Rotea system aims to help researchers overcome manufacturing hurdles and bring the vast potential of cell therapies to more patients

Find out how experts at the Ellison Institute are harnessing new cell monitoring technology to build cancer cell biobanks and enhance cell line quality control and authentication

The Phase II clinical trial, which will use cutting-edge CRISPR genetic engineering, has already begun enrolling patients

The addition of COVID-19 antibody tests to the portfolio aims to further support the pandemic response on multiple fronts